• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Minimum Technical Data Elements for Liquid Biopsy Data Submitted to Public Databases.

作者信息

Febbo Phillip G, Martin Anne-Marie, Scher Howard I, Barrett J Carl, Beaver Julia A, Beresford Paul J, Blumenthal Gideon M, Bramlett Kelli, Compton Carolyn, Dittamore Ryan, Eberhard David A, Edelstein Daniel, Godsey James, Gruen Andrew, Hanlon Sean E, Hicks James, Hovelson Daniel, Hullings Melanie, Johann Donald, Johnson Justin, Kolatkar Anand, Kuhn Peter, Levine Rebecca, Martini Jean-Francois, Miller Daniel P, Moore Carissa, Moy Bryan, Pathak Anand, Philip Reena, Reese David, Royalty Wendy, Ryder Matthew, Sakul Hakan, Salvatore Lea M, Schade Andrew, Silvestro Angela, Simmons John K, Simons Jonathan, Singh Bhan Seema, Smalley Matthew D, Somiari Stella B, Talasaz AmirAli, Tewari Muneesh, Tseng Hsian-Rong, Vinson Jake, Wells Walt, Welsh Allison, Grossman Robert L, Lee Jerry S H, Leiman Lauren C

机构信息

Illumina, San Diego, California, USA.

Novartis Pharmaceuticals, East Hanover, New Jersey, USA.

出版信息

Clin Pharmacol Ther. 2020 Apr;107(4):730-734. doi: 10.1002/cpt.1747. Epub 2020 Feb 4.

DOI:10.1002/cpt.1747
PMID:32017048
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7158216/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0843/7158216/d21df2027c24/CPT-107-730-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0843/7158216/d21df2027c24/CPT-107-730-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0843/7158216/d21df2027c24/CPT-107-730-g001.jpg

相似文献

1
Minimum Technical Data Elements for Liquid Biopsy Data Submitted to Public Databases.提交至公共数据库的液体活检数据的最低技术数据元素
Clin Pharmacol Ther. 2020 Apr;107(4):730-734. doi: 10.1002/cpt.1747. Epub 2020 Feb 4.
2
National Cancer Database: The Past, Present, and Future of the Cancer Registry and Its Efforts to Improve the Quality of Cancer Care.国家癌症数据库：癌症登记处的过去、现在和未来及其改善癌症护理质量的努力。
Semin Radiat Oncol. 2019 Oct;29(4):323-325. doi: 10.1016/j.semradonc.2019.05.005.
3
[Practical use of biobank information management system (BIMS) for clinical-biological annotations in biobanks].生物样本库信息管理系统（BIMS）在生物样本库临床生物学注释中的实际应用
Med Sci (Paris). 2020 Mar;36(3):285-288. doi: 10.1051/medsci/2020044. Epub 2020 Mar 31.
4
Role of public-private partnerships in achieving UNAIDS HIV treatment targets.公私伙伴关系在实现联合国艾滋病规划署艾滋病治疗目标中的作用。
BMC Health Serv Res. 2019 Jan 18;19(1):46. doi: 10.1186/s12913-018-3744-z.
5
Role of Academic Biobanks in Public-Private Partnerships in the European Biobanking and BioMolecular Resources Research Infrastructure Community.学术生物样本库在欧洲生物样本库与生物分子资源研究基础设施社区公私合作伙伴关系中的作用。
Biopreserv Biobank. 2019;17(1):46-51. doi: 10.1089/bio.2018.0024. Epub 2018 Nov 30.
6
How to Achieve Transparency in Public-Private Partnerships Engaged in Hunger and Malnutrition Reduction.如何在致力于减少饥饿与营养不良的公私伙伴关系中实现透明度。
World Rev Nutr Diet. 2016;115:224-32. doi: 10.1159/000442109. Epub 2016 May 19.
7
Reflections on the Clinical Research Enterprise: Past, Present and Future.对临床研究事业的反思：过去、现在与未来
Circulation. 2018 Oct 23;138(17):1765-1770. doi: 10.1161/CIRCULATIONAHA.118.037900.
8
Availability of public databases for triangulation of findings.用于结果三角验证的公共数据库的可用性。
Proc Natl Acad Sci U S A. 2019 Aug 6;116(32):15766-15767. doi: 10.1073/pnas.1908893116. Epub 2019 Jul 23.
9
District decision-making for health in low-income settings: a qualitative study in Uttar Pradesh, India, on engaging the private health sector in sharing health-related data.低收入环境下的地区卫生决策：印度北方邦关于促使私营卫生部门共享健康相关数据的一项定性研究
Health Policy Plan. 2016 Sep;31 Suppl 2(Suppl 2):ii35-ii46. doi: 10.1093/heapol/czv117.
10
A standardized citation metrics author database annotated for scientific field.标准化引文计量作者数据库，标注了科学领域。
PLoS Biol. 2019 Aug 12;17(8):e3000384. doi: 10.1371/journal.pbio.3000384. eCollection 2019 Aug.

引用本文的文献

1
Shining the Path of Precision Diagnostic: Advancements in Photonic Sensors for Liquid Biopsy.照亮精准诊断之路：液体活检光子传感器的进展
Biosensors (Basel). 2025 Jul 22;15(8):473. doi: 10.3390/bios15080473.
2
Minimum Technical Preanalytical, Patient, and Clinical Context Data Elements for Cerebrospinal Fluid Liquid Biopsy: Recommendations for Public Database Submissions.脑脊液液体活检的最低技术分析前、患者及临床背景数据元素：公共数据库提交建议
JCO Precis Oncol. 2025 Jun;9:e2400921. doi: 10.1200/PO-24-00921. Epub 2025 Jun 26.
3
Liquid Biopsy: The Challenges of a Revolutionary Approach in Oncology.

本文引用的文献

1
Preanalytics and Precision Pathology: Pathology Practices to Ensure Molecular Integrity of Cancer Patient Biospecimens for Precision Medicine.前分析和精准病理学：为精准医学确保癌症患者生物标本分子完整性的病理学实践。
Arch Pathol Lab Med. 2019 Nov;143(11):1346-1363. doi: 10.5858/arpa.2019-0009-SA. Epub 2019 Jul 22.
2
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.循环肿瘤 DNA 分析在癌症患者中的应用：美国临床肿瘤学会和美国病理学家学会联合审查。
Arch Pathol Lab Med. 2018 Oct;142(10):1242-1253. doi: 10.5858/arpa.2018-0901-SA. Epub 2018 Mar 5.
3
液体活检：肿瘤学中一种革命性方法面临的挑战
Int J Mol Sci. 2025 May 23;26(11):5013. doi: 10.3390/ijms26115013.
4
Blood collection tube and RNA purification method recommendations for extracellular RNA transcriptome profiling.用于细胞外RNA转录组分析的采血管及RNA纯化方法建议
Nat Commun. 2025 May 15;16(1):4513. doi: 10.1038/s41467-025-58607-7.
5
Recommended Clinical Context and Patient Context Data Elements for Liquid Biopsy Data Submitted to Data Repositories and Data Commons.提交至数据储存库和数据共享平台的液体活检数据的推荐临床背景和患者背景数据元素。
Clin Transl Sci. 2025 Apr;18(4):e70227. doi: 10.1111/cts.70227.
6
Modulating cell-free DNA biology as the next frontier in liquid biopsies.调控游离DNA生物学作为液体活检的下一个前沿领域。
Trends Cell Biol. 2025 Jun;35(6):459-469. doi: 10.1016/j.tcb.2024.11.007. Epub 2024 Dec 26.
7
Leptomeningeal metastatic disease: new frontiers and future directions.软脑膜转移瘤：新前沿与未来方向。
Nat Rev Clin Oncol. 2025 Feb;22(2):134-154. doi: 10.1038/s41571-024-00970-3. Epub 2024 Dec 9.
8
Towards Preanalytical Best Practices for Liquid Biopsy Studies: A BLOODPAC Landscape Analysis.迈向液体活检研究的分析前最佳实践：一项BLOODPAC态势分析
Clin Pharmacol Ther. 2025 Jan;117(1):28-33. doi: 10.1002/cpt.3416. Epub 2024 Aug 20.
9
Advancing Evidence Generation for Circulating Tumor DNA: Lessons Learned from A Multi-Assay Study of Baseline Circulating Tumor DNA Levels across Cancer Types and Stages.循环肿瘤DNA的证据生成进展：来自不同癌症类型和阶段基线循环肿瘤DNA水平多检测研究的经验教训
Diagnostics (Basel). 2024 Apr 27;14(9):912. doi: 10.3390/diagnostics14090912.
10
Detection of chromosomal instability using ultrasensitive chromosomal aneuploidy detection in the diagnosis of precancerous lesions of gastric cancer.利用超灵敏染色体非整倍体检测技术检测染色体不稳定性在胃癌癌前病变诊断中的应用
Front Genet. 2024 Apr 9;15:1359231. doi: 10.3389/fgene.2024.1359231. eCollection 2024.
Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy.
了解分析前变量及其对肿瘤学和免疫治疗临床生物标志物的影响。
Semin Cancer Biol. 2018 Oct;52(Pt 2):26-38. doi: 10.1016/j.semcancer.2017.12.008. Epub 2017 Dec 16.
4
Collaborating to Compete: Blood Profiling Atlas in Cancer (BloodPAC) Consortium.合作以竞争：癌症血液图谱联盟（BloodPAC）
Clin Pharmacol Ther. 2017 May;101(5):589-592. doi: 10.1002/cpt.666. Epub 2017 Apr 12.
5
Comparative analysis of circulating tumor DNA stability In KEDTA, Streck, and CellSave blood collection tubes.KEDTA、Streck和CellSave采血管中循环肿瘤DNA稳定性的比较分析
Clin Biochem. 2016 Dec;49(18):1354-1360. doi: 10.1016/j.clinbiochem.2016.03.012. Epub 2016 Apr 27.
6
Development and use of integral assays in clinical trials.积分测定法在临床试验中的开发与应用。
Clin Cancer Res. 2012 Mar 15;18(6):1540-6. doi: 10.1158/1078-0432.CCR-11-2202.
7
Impact of preanalytic factors on the design and application of integral biomarkers for directing patient therapy.分析前因素对指导患者治疗的整体生物标志物的设计和应用的影响。
Clin Cancer Res. 2012 Mar 15;18(6):1524-30. doi: 10.1158/1078-0432.CCR-11-2204.
8
Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development.拉平起跑线：使生物标志物和分子诊断的发展达到药物开发的标准。
Clin Cancer Res. 2012 Mar 15;18(6):1515-23. doi: 10.1158/1078-0432.CCR-11-2206.
9
Sources of bias in specimens for research about molecular markers for cancer.用于癌症分子标志物研究标本的偏倚来源。
J Clin Oncol. 2010 Feb 1;28(4):698-704. doi: 10.1200/JCO.2009.25.6065. Epub 2009 Dec 28.
10
Validation of analytic methods for biomarkers used in drug development.用于药物研发的生物标志物分析方法的验证。
Clin Cancer Res. 2008 Oct 1;14(19):5967-76. doi: 10.1158/1078-0432.CCR-07-4535.